<DOC>
	<DOC>NCT00373646</DOC>
	<brief_summary>The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.</brief_summary>
	<brief_title>Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients</brief_title>
	<detailed_description>The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients with histologically confirmed MALT lymphoma with measurable disease (Stage IIV) With first or greater relapse after HPeradication, radiation or chemotherapy Age &gt; 18 Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function ECOG status _&lt; 2 Must be capable of understanding the purpose of the study and have given written informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>MALT Lymphoma</keyword>
	<keyword>thalidomide</keyword>
	<keyword>disseminated MALT Lymphoma or at relapse following HP-eradication</keyword>
	<keyword>or chemotherapy or radiation</keyword>
</DOC>